Natco Pharma Ltd

524816

Summary

Fair Value Assessment
Undervalued (4% Discount)
Fair ValueQ810.59UncertaintyHigh
Close Price771.65Feb 28, 2025
Market Closed
771.65
Price Down by 28.15 | 3.52 %
Previous Close
771.65
Day Range
757.75 – 792.00
Year Range
757.75 – 1,638.35
Bid / Ask
Market Cap
138.2 Bil
Volume / Average
175.5 k / 58.5 k
Beta (5-Year)
0.81
Shares Outstanding
179.11 Mil
Primary Exchange
Bombay Stock Exchange

Business Description
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
Contact
Road No. 2, NATCO House Banjara Hills, Hyderabad, TG 500034
T +91 4023547532
www.natcopharma.co.in opens in a new tab
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Dec 31, 2024
Fiscal Year End
Mar 31, 2025
Employees
4,762

Key Metrics

Income Statement (in Bil, except ratios)
12/31/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Revenue
42.57 39.79 26.97 19.05 16.90 18.88
Revenue Growth %
11.49% 47.53% 41.58% 12.70% -10.46% -8.44%
Gross Profit
35.28 31.16 19.51 12.23 10.82 13.78
Gross Profit Margin %
82.87% 78.32% 72.36% 64.22% 64.04% 72.98%
Operating Income
19.65 15.77 7.90 1.42 5.01 4.91
Operating Margin %
46.16% 39.63% 29.30% 7.48% 29.64% 26.02%
EBIT
21.75 15.85 8.20 1.76 5.32 5.07
EBIT Margin %
51.09% 39.82% 30.41% 9.26% 31.46% 26.87%
EBITDA
23.67 17.71 9.84 3.19 6.49 6.07
EBITDA Margin %
55.61% 44.52% 36.49% 16.75% 38.38% 32.16%
Net Income
18.65 13.88 7.15 1.70 4.41 4.61
Net Profit Margin %
43.78% 34.89% 26.52% 8.92% 26.17% 24.27%
Basic EPS
104.12 77.34 39.18 9.32 24.20 25.33
Diluted EPS
104.12 77.34 39.18 9.32 24.16 25.26
Normalized EPS
103.99 77.45 39.77 7.79 23.79 25.19
Total Dividends per Share
5.75 9.50 5.50 4.50 6.25 7.00
Balance Sheet (in Bil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Total Assets
82.45 69.06 56.57 51.09 47.92 45.88
Total Liabilities
10.88 10.53 7.84 8.46 6.69 8.03
Total Debt
2.08 3.86 1.76 4.32 2.84 3.29
Total Equity
71.57 58.53 48.74 42.64 41.23 37.85
Cash And Cash Equivalents
1.05 0.70 1.32 1.11 0.26 0.20
Working Capital
39.93 30.51 23.17 17.87 18.12 16.40
Shares Outstanding (Bil)
Book Value Per Share
326.79 267.10 233.41 225.08 205.97
Total Debt To Equity
0.03 0.07 0.04 0.10 0.07 0.09
Cash Flow Statement (in Bil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Cash From Operating Activities
17.16 12.12 8.49 0.47 2.99 4.17
Cash From Investing Activities
-15.67 -10.33 -4.77 -0.05 -1.03 -1.67
Cash From Financing Activities
-1.52 -2.47 -3.63 0.35 -1.86 -2.51
Capital Expenditures
3.59 2.06 2.43 2.55 3.59
Free Cash Flow
11.44 5.67 0.18 2.44 1.34
Change in Cash
-0.02 -0.68 0.09 0.76 0.10 -0.01

Profile

Name (Age)
5-Year Trend
2021
2022
2023
2024
2025
Rajeev Nannapaneni (47) Executive Vice Chairman of the Board and Chief Executive Officer
Pavan Ganapati Bhat (56) Director and Executive Vice President, Technical Operations
Linga Rao Donthineni (72) Director and President, Technical Affairs
Venkaiah Chowdary Nannapaneni (79) Executive Chairman of the Board and Managing Director
Potluri Prasad Sivaramakrishna (66) Director and Executive Vice President, Corporate Engineering Services
Total Compensation for all Key Executives
Transaction History

Shares in Thousands
0 5 10 15 20 25 30 35 40
>
No Data Available
There is no available information for this investment.
Sep
2023
    • Buy
    • Acquisition
    • Option Exercise
    • Disposition
    • Sell
Transaction Detail
No Data Available
There is no available information for this investment.

Ownership

Name
% Total
Shares Held
% Total
Assets
Trend
Prev. 8 Qtrs
Change Amount
Change %
Date
Tata Equity P/E Reg Gr 0.93 2.42 1,665,000
36,000
2.21%
Jan 31, 2025
Vanguard Total Intl Stock Index Inv 0.69 0.00 1,237,793
Jan 31, 2025
Vanguard Emerging Mkts Stock Idx Inv 0.65 0.01 1,164,853
Jan 31, 2025
iShares Core MSCI Emerging Markets ETF 0.48 0.01 858,733
Feb 26, 2025
Jupiter India L Acc 0.43 0.46 762,896
Nov 30, 2024
Total (for Top 5) 3.18 5,689,275
36,000

© Copyright 2025 Morningstar, Inc. All rights reserved.
Terms of Use    Privacy Policy
© Copyright 2025 Morningstar, Inc. All rights reserved. Please read our Terms of Use above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
As of December 1st, 2023, the ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
Company: Morningstar India Private Limited; Regd. Office: 9th floor, Platinum Technopark, Plot No. 17/18, Sector 30A, Vashi, Navi Mumbai – 400705, Maharashtra, India; CIN: U72300MH2004PTC245103; Telephone No.: +91-22-61217100; Fax No.: +91-22-61217200; Contact: Morningstar India Help Desk (e-mail: helpdesk.in@morningstar.com) in case of queries or grievances.
Top